发明名称 Inhibitors of PDE4 enzyme and antagonists of muscarinic M3 receptor
摘要 Compounds of formula (I) described herein are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.
申请公布号 US9169245(B2) 申请公布日期 2015.10.27
申请号 US201314097397 申请日期 2013.12.05
申请人 Chiesi Farmaceutici S.p.A. 发明人 Armani Elisabetta;Amari Gabriele;Riccaboni Mauro;Baker-Glenn Charles
分类号 C07D453/02;C07D453/00;C07D401/14;C07D401/12;C07D417/14;C07D417/12;A61K31/444;A61K31/4427;A61M15/00;A61P11/00;A61P11/06 主分类号 C07D453/02
代理机构 Oblon, McClelland, Maier & Neustadt, L.L.P. 代理人 Oblon, McClelland, Maier & Neustadt, L.L.P.
主权项 1. A compound represented by formula (I):wherein: R1 and R2 are different or the same and are: H; (C3-C7) cycloalkylcarbonyl; (C1-C6) alkyl, optionally substituted by one or more substituents selected from the group consisting of (C3-C7) cycloalkyl and (C5-C7) cycloalkenyl; (C1-C6) haloalkyl; (C3-C7) cycloalkyl; (C5-C7) cycloalkenyl; (C2-C6) alkenyl; or (C2-C6) alkynyl; or R1 and R2, together with the interconnecting atoms, form a 2,2-difluoro-1,3-dioxolane ring represented by formula (r) fused to the phenyl moiety which bears groups —OR1 and —OR2, wherein asterisks indicate carbon atoms shared with the phenyl ring: each R3 is independently CN, NO2, CF3, or a halogen atom; k is zero or an integer ranging from 1 to 3; A is a saturated and monocyclic (C3-C7) heterocycloalkylene group; W is: [1]-(CH2)sC(O)-[2] wherein s is zero or 1;[1]-C(O)(CH2)j[2], wherein j is 1 or 2;[1]-SO2 (CH2)t-[2] wherein t is zero, 1 or 2;[1]-(CH2)ySO2-[2] wherein y is 1 or 2;[1](CH2)f-[2] wherein f is 1 or 2; or[1]C(O)(CH2)2SO2-[2]; wherein [1] and [2] indicate the points of attachment for group W with, respectively, ring A and the phenyl moiety; each R4 is hydrogen, halogen, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4)haloalkyl, hydroxy, —SO2NR5R6, —CN, or —NR7SO2R8, and wherein said (C1-C4) alkyl and said (C1-C4) alkoxy are optionally substituted by one (C3-C7) cycloalkyl group, R5 is hydrogen or (C1-C6) alkyl;R6 is hydrogen or (C1-C6) alkyl;R7 is hydrogen or (C1-C6) alkyl;R8 is hydrogen or (C1-C6) alkyl; m is an integer ranging from 1 to 3; B is selected from: a group represented by formula (a) wherein the asterisk indicates the point of attachment for group B to the phenyl ring: wherein p is zero or 1; q is zero or 1; each R9 is independently halogen, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4)haloalkyl, hydroxy, —SO2NR10R11, —CN, or —NR12SO2R13, and wherein said (C1-C4) alkyl and said (C1-C4) alkoxy are optionally substituted by one (C3-C7) cycloalkyl group, R10 is hydrogen or (C1-C6) alkyl;R11 is hydrogen or (C1-C6) alkyl;R12 is hydrogen or (C1-C6) alkyl;R13 is hydrogen or (C1-C6) alkyl; n is an integer ranging from 1 to 3; E is a nitrogen containing group which is: a group (c) which is —(CH2)g—NR14R15 wherein g is an integer ranging from 1 to 4 and R14 and R15 are independently hydrogen or (C1-C4) alkyl; ora group (d) which is a saturated monocyclic or bicyclic or tricyclic heterocyclic ring system optionally substituted by one or two groups R16 which are at each occurrence are independently (C1-C4) alkyl or benzyl; a group of formula (b) wherein the asterisk indicates the point of attachment for group B to the phenyl ring: wherein R17 is hydrogen, (C1-C4) alkyl, or —SO2(C1-C4)alkyl; R18 is an aryl group or a 5 to 11 membered heteroaryl group, wherein said aryl group and said heteroaryl group are optionally substituted by 1 to 3 groups R19; R19 is at each occurrence independently halogen, (C1-C4)haloalkyl, hydroxy, —SO2NR20R21, —CN, —NR22SO2R23, (C1-C4) alkyl, or (C1-C4) alkoxy wherein said (C1-C4) alkyl and said (C1-C4) alkoxy are optionally substituted by one (C3-C7) cycloalkyl group, and whereinR20 is hydrogen or (C1-C6) alkyl;R21 is hydrogen or (C1-C6) alkyl;R22 is hydrogen or (C1-C6) alkyl;R23 is hydrogen or (C1-C6) alkyl; Z is a bond or a divalent radical which is —(CH2)—, —(CH2)2—, —S—, —S(O)—, —S(O2)—, —C(O)—, or a group [5]-(C1-C4)alkylOC(O)-[6], wherein [5] and [6] represent, respectively the point of attachment of group Z to the phenyl ring and to the nitrogen atom; and E is a group as above defined or an N-oxide on the pyridine ring, or a pharmaceutically acceptable salt thereof.
地址 Parma IT